Please login to the form below

Not currently logged in
Email:
Password:

dabigatran

This page shows the latest dabigatran news and features for those working in and with pharma, biotech and healthcare.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Ingelheim’s thrombin inhibitor Pradaxa (dabigatran).

Latest news

More from news
Approximately 9 fully matching, plus 70 partially matching documents found.

Latest Intelligence

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    American College of Cardiology (ACC) to educate cardiologists in China about stroke prevention in atrial fibrillation (AF) – a condition for which Boehringer markets Pradaxa (dabigatran).

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Between March 2011 and February 2012, dabigatran etexilate sales crossed the 'blockbuster' $1bn threshold. ... Interestingly, a study published in Stroke in March 2012 found that dabigatran etexilate was a cost-effective alternative to warfarin.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics